Merck's Vioxx cases drag on

August 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

An estimated 45,000 people have sued Merck, contending the drug caused heart attacks and strokes. Merck has spent more than $1 billion on legal fees during the last three years on Vioxx cases and has vowed to contest each lawsuit, The New York Times reported Tuesday.

Merck, the third-largest U.S. drug maker, is betting its aggressive resistance will reduce the number of cases and, ultimately, its liability, the Times reported. The result is a legal limbo in which even those who have won a case against Merck have yet to see any money because Merck immediately appeals, the newspaper said.

Estimates of Merck's liability, once as high as $25 billion, now is closer to $5 billion, corporate risk analysts told the Times.

Copyright 2007 by United Press International

Explore further: Mass. doctor accused of faking pain pill data

Related Stories

Mass. doctor accused of faking pain pill data

March 11, 2009

(AP) -- A Massachusetts anesthesiologist has been accused of faking data for a dozen years in 21 published studies that suggested after-surgery benefits from painkillers including Vioxx and Celebrex.

Study: Vioxx poses even short-term risks

May 3, 2006

A Montreal study raises questions about even short-term use of the pain drug Vioxx and may harm Merck & Co.'s defense against 11,500 lawsuits, a report said.

New Algorithms Identify Side Effects of Prescription Drugs

February 22, 2010

( -- We're all used to hearing disclaimers about prescription drug side effects. They drone on in television commercials and take up pages of tiny print accompanying the prescriptions themselves. But with an estimated ...

When is a drug too risky to stay on the market?

June 30, 2010

(AP) -- The arthritis pill Vioxx was withdrawn but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to ...

Study finds that vioxx reduces the risk of colorectal polyps

August 30, 2006

A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX®) reduces the risk of colorectal adenomas, or polyps. Polyps are benign tumors that ...

FDA proposal on drug articles under fire

April 20, 2008

Claims that the pharmaceutical company Merck hired ghostwriters for Vioxx articles has put heat on a U.S. proposal to loosen drug promotion rules.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.